volasertib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Volasertib is an experimental small molecule inhibitor of the PLK1 protein being developed by Boehringer Ingelheim for use as an anti-cancer agent. Volasertib is the second in a novel class of drugs called dihydropteridinone derivatives.   Wikipedia

Chemistry

  • SMILES: CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C
  • InChIKey: SXNJFOWDRLKDSF-STROYTFGSA-N
  • Mol. Mass: 618.83
  • ALogP: 4.27
  • ChEMBL Molecule:
    volasertib  
More Chemistry

Pharmacology

Alternative names

bi 6727 | bi-6727 | volasertib

Organizations (11)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (16)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (16)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Leukemia (Phase 1)

Leukemia, Erythroblastic, Acute (Phase 1)

Leukemia, Megakaryoblastic, Acute (Phase 1)

Leukemia, Monocytic, Acute (Phase 1)

Leukemia, Myeloid, Acute (Phase 3)

Leukemia, Myelomonocytic, Acute (Phase 1)

Leukemia, Myelomonocytic, Chronic (Phase 1)

Lymphoma (Phase 1)

Lymphoma, T-Cell (Phase 1)

Lymphoma, T-Cell, Cutaneous (Phase 1)

Lymphoma, T-Cell, Peripheral (Phase 1)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 26
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue